|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012 v1.0, cancer incidence and mortality
Worldwide: IARC CancerBase No. 11 [Internet]International agency
for research on cancer. Lyon: 2013, http://globocan.iarc.frMarch 21–2018
|
|
2
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Novello S, Barlesi F, Califano R, Cufer T,
Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, et al:
Metastatic non-small-cell lung cancer: ESMO clinical practice
guidelines for diagnosis, treatment and follow-up. Ann Oncol. 27
Suppl 5:v1–v27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sakhri L, Meynet E, Ferrer L, Pirvu A,
Ferretti G and Moro-Sibilot D: Atypical response to erlotinib in a
patient with metastatic lung adenocarcinoma: A case report. J Med
Case Rep. 8:3352014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ryu YJ, Chun EM, Lee SN and Shim SS:
Progressive multiple cystic changes in both lungs in a patient
treated with gefitinib for lung adenocarcinoma with multiple lung
metastases. Korean J Radiol. 15:300–304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baybutt RC, Smith BW, Donskaya EV, Hu L,
Li T and Wang W: The proliferative effects of retinoic acid on
primary cultures of adult rat type II pneumocytes depend upon cell
density. In Vitro Cell Dev Biol Anim. 46:20–27. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Higenbottam T, Kuwano K, Nemery B and
Fujita Y: Understanding the mechanisms of drug-associated
interstitial lung disease. Br J Cancer. 91 Suppl 2:S31–S37. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shepherd FA, Pereira Rodrigues J, Ciuleanu
T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S,
Smylie M, Martins R, et al: Erlotinib in previously treated
non-small-cell lung cancer. N Engl J Med. 353:123–132. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lind JS, Smit EF, Grünberg K, Senan S and
Lagerwaard FJ: Fatal Interstitial lung disease after erlotinib for
non-small cell lung cancer. J Thorac Oncol. 3:1050–1053. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vahid B and Esmaili A:
Erlotinib-associated acute pneumonitis: Report of two cases. Can
Respir J. 14:167–170. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chou CL, Ko HW, Wang CW, Yu CT, Kuo HP and
Huang CD: Erlotinib-associated near-fatal interstitial pneumonitis
in a patient with relapsed lung adenocarcinoma. Chang Gung Med J.
33:100–105. 2010.PubMed/NCBI
|
|
12
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Choi H, Charnsangavej C, Faria SC,
Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA and
Benjamin RS: Correlation of computed tomography and positron
emission tomography in patients with metastatic gastrointestinal
stromal tumor treated at a single institution with imatinib
mesylate: Proposal of new computed tomography response criteria. J
Clin Oncol. 25:1753–1759. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee HY, Lee KS, Ahn MJ, Hwang HS, Lee JW,
Park K, Ahn JS, Kim TS, Yi CA and Chung MJ: New CT response
criteria in non-small cell lung cancer: Proposal and application in
EGFR tyrosine kinase inhibitor therapy. Lung Cancer. 73:63–69.
2011. View Article : Google Scholar : PubMed/NCBI
|
